Bull Pharmachem
Bull Pharmachem
Kalbadevi, Mumbai, Maharashtra
GST No. 27AKFPJ6383E1Z2
TrustSEAL Verified
Call 08048419840 88% Response Rate
SEND EMAIL

Central Nervous System

Offering you a complete choice of products which include ocrelizumab  300 mg, ocrevus (ocrelizumab 300 mg), sabril (vigabatrin 500mg), vigabatrin 500mg and koselugo (selumetinib 25mg,10mg).

Ocrelizumab  300 Mg

Ocrelizumab  300 Mg
  • Ocrelizumab  300 Mg
Get Best Quote
Approx. Price: Rs 10 / BottleGet Latest Price

Product Details:

Packaging Size1 Vial
TreatmentMultiple Sclerosis
Prescription/Non prescriptionPrescription
Usage/ApplicationHospital
CompositionOcrelizumab
DoseTake Ocrelizumab vial only as per the dose and duration suggested by your doct
Medicine TypeInjection
Preferred Mode Of TreatmentHospitals

Ocrelizumab 300mg injection is acd20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.
what are side effects ofocrelizumab? Common side effects ofocrelizumab include:
upper respiratory tract infections,infusion reactions (itching, rash, hives, redness, bronchospasm, swollen and sore throat, mouth pain, shortness of breath, flushing, hypotension, fever, fatigue, headache, dizziness, nausea, and fast heart rate),skin infections,lower respiratory tract infections,depression,back pain, andpain in the extremities. Dosage forocrelizumabhepatitis b virus screening is required before the first dose ofocrelizumab. Pre-medicate with methylprednisolone (or an equivalent corticosteroid) and an antihistamine prior to each infusion. The starting dose ofocrelizumab is 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion. Subsequent doses ofocrelizumab are 600 mg intravenous infusion every 6 months.
what drugs, substances, or supplements interact withocrelizumab? Ocrevus may interact with other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids. Tell your doctor all medications and supplements you use.
ocrevus during pregnancy and breastfeedingocrevus is not recommended for use during pregnancy; it may harm a fetus. It is unknown ifocrelizumab passes into breast milk. Consult your doctor before breastfeeding.
additional informationourocrelizumab (ocrelizumab) injection side effects drug center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
this is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to fda at 1-800-fda-1088.

some side effects may occur during the injection or up to 24 hours later. Tell your caregiver right away if you feel dizzy, tired, nauseated, light-headed, feverish, sweaty, itchy, or have a red skin rash, headache, fast heartbeats, chest tightness, trouble breathing, or swelling and irritation in your throat.
fast heart beats, tiredness;headache, nausea, dizziness;itchy skin, rash, hives;fever, chills, cough;throat pain or irritation;wheezing, breathing problem, feeling short of breath;flushing (sudden warmth, redness, or tingly feeling);skin sores, blisters, pus, or oozing;cold sores or fever blisters on or around your lips;nerve pain (tingling, burning pain, "pins and needles" feeling);mood or behavior changes, confusion, memory problems;weakness on one side of your body; orproblems with speech, vision, or muscle movement. Your ocrelizumab treatments may be delayed or permanently discontinued if you have certain side effects.
common side effects may include:
skin infections;reactions to an injection; orcold symptoms such as stuffy nose, sneezing, sore throat.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Ocrevus (Ocrelizumab 300 MG)

Ocrevus (Ocrelizumab 300 MG)
  • Ocrevus (Ocrelizumab 300 MG)
  • Ocrevus (Ocrelizumab 300 MG)
  • Ocrevus (Ocrelizumab 300 MG)
Ask For Price
Product Price :Get Latest Price

Product Details:

Strength300mg
Packaging Size1vial
BrandOcrevus
CompositionOcrelizumab
ManufacturerRoche Products (India) Pvt. Ltd.
TreatmentMultiple Sclerosis
Prescription/Non prescriptionPrescription
FormInjection
Deals inThird Party Manufacturing
Shelf life2 Years

Ocrevus (Ocrelizumab 300mg) injection is aCD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis.
What Are Side Effects of Ocrevus?Common side effects of Ocrevus include:
upper respiratory tract infections,infusion reactions (itching, rash, hives, redness, bronchospasm, swollen and sore throat, mouth pain, shortness of breath, flushing, hypotension, fever, fatigue, headache, dizziness, nausea, and fast heart rate),skin infections,lower respiratory tract infections,depression,back pain, andpain in the extremities.Dosage for OcrevusHepatitis B virus screening is required before the first dose of Ocrevus. Pre-medicate with methylprednisolone (or an equivalent corticosteroid) and an antihistamine prior to each infusion. The starting dose of Ocrevus is 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion. Subsequent doses of Ocrevus are 600 mg intravenous infusion every 6 months.
What Drugs, Substances, or Supplements Interact with Ocrevus?Ocrevus may interact with other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids. Tell your doctor all medications and supplements you use.
Ocrevus During Pregnancy and BreastfeedingOcrevus is not recommended for use during pregnancy; it may harm a fetus. It is unknown if Ocrevus passes into breast milk. Consult your doctor before breastfeeding.
Additional InformationOur Ocrevus (ocrelizumab) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Some side effects may occur during the injection or up to 24 hours later. Tell your caregiver right away if you feel dizzy, tired, nauseated, light-headed, feverish, sweaty, itchy, or have a red skin rash, headache, fast heartbeats, chest tightness, trouble breathing, or swelling and irritation in your throat.
fast heart beats, tiredness;headache, nausea, dizziness;itchy skin, rash, hives;fever, chills, cough;throat pain or irritation;wheezing, breathing problem, feeling short of breath;flushing (sudden warmth, redness, or tingly feeling);skin sores, blisters, pus, or oozing;cold sores or fever blisters on or around your lips;nerve pain (tingling, burning pain, "pins and needles" feeling);mood or behavior changes, confusion, memory problems;weakness on one side of your body; orproblems with speech, vision, or muscle movement.Your ocrelizumab treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects may include:
skin infections;reactions to an injection; orcold symptoms such as stuffy nose, sneezing, sore throat.
Request
Callback


Additional Information:

  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Sabril (Vigabatrin 500mg)

Sabril (Vigabatrin 500mg)
  • Sabril (Vigabatrin 500mg)
  • Sabril (Vigabatrin 500mg)
  • Sabril (Vigabatrin 500mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Box
CompositionVigabatrin
FormTablets
Packaging Size100 Tablets
Brand NameSabril
DosageTake Sabril Tablet only as per the dose and duration suggested by your doctor.
Packaging TypeBox
Deals inThird Party Manufacturing
Type Of MedicinesAllopathic
ManufacturerSanofi Aventis
TreatmentSeizures

SABRIL (vigabatrin 500mg) is a prescription medicine used with other treatments in adults and children 2 years of age and older with refractory complex partial seizures (CPS) who have not responded well enough to several other treatments and if the possible benefits outweigh the risk of vision loss. SABRIL should not be the first medicine used to treat CPS. Because SABRIL might cause permanent vision loss, it is available to healthcare providers and patients only under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program. Your healthcare provider will explain the details of this Program to you. SABRIL can damage the vision of anyone who takes it. Some people can have severe loss particularly to their ability to see to the side when looking straight ahead (peripheral vision). With severe vision loss, you may only be able to see things straight in front of you (sometimes called "tunnel vision"). You may also have blurry vision. If this happens, it will not get better. Tell your healthcare provider right away if you (or your child): might not be seeing as well as before starting SABRIL; start to trip, bump into things, or are more clumsy than usual; are surprised by people or things coming in front of you that seem to come out of nowhere; or if your baby is acting differently than normal. These changes can mean that vision damage has occurred. It is recommended that your healthcare provider test your (or your child’s) vision before or within 4 weeks after starting SABRIL, and at least every 3 months during treatment until SABRIL is stopped. It is also recommended that vision be tested about 3 to 6 months after SABRIL is stopped. Your vision loss may get worse after you stop taking SABRIL. It is difficult to test vision in babies, but to the extent possible, all babies should have their vision tested. Your healthcare provider will determine if testing can be done. Regular vision testing is important because damage can happen before any changes are noticed. Vision tests cannot prevent the vision damage that can happen with SABRIL, but they do allow SABRIL to be stopped if vision has gotten worse. Even these regular vision tests may not show vision damage before it is severe and permanent. Parents, caregivers, and healthcare providers may not recognize the symptoms, or find vision loss in babies, until it is severe. If vision tests are not done regularly, your healthcare provider may stop prescribing SABRIL for you (or your child). Some people are not able to complete vision testing. If vision testing cannot be done, your healthcare provider may continue prescribing SABRIL, but will not be able to watch for any vision loss. Brain pictures taken by magnetic resonance imaging (MRI) show changes in some babies after they are given SABRIL. It is not known if these changes are harmful. A type of swelling in the brain called Intramyelinic Edema (IME) has been seen in autopsy examination of babies treated with vigabatrin. Like other antiepileptic drugs, SABRIL may cause suicidal thoughts and actions in some people. Call a healthcare provider right away if you (or your child) have any symptoms, especially sudden changes in mood, behaviors, thoughts or feelings, and especially if they are new, worse, or worry you. Do not stop SABRIL without first talking to a healthcare provider. Stopping SABRIL suddenly can cause seizures that will not stop. SABRIL can cause serious side effects such as low red blood cell counts (anemia), sleepiness and tiredness, nerve problems, weight gain, and swelling. Because SABRIL causes sleepiness and tiredness, do not drive, operate machinery, or perform any hazardous task, unless it is decided that these things can be done safely. SABRIL may make certain types of seizures worse. Tell your healthcare provider right away if seizures get worse.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Vigabatrin 500mg

Vigabatrin 500mg
  • Vigabatrin 500mg
  • Vigabatrin 500mg
  • Vigabatrin 500mg
Ask For Price
Product Price :Get Latest Price

Product Details:

CompositionVigabatrin
FormTablets
Packaging Size100 Tablets
DosageTake Vigabatrin Tablet only as per the dose and duration suggested by your doctor.
Packaging TypeBox
Deals inThird Party Manufacturing
Type Of MedicinesAllopathic
TreatmentSeizures
Shelf life2 Years
Storage20 DegreeC to 25 DegreeC (68 DegreeF to 77 DegreeF)

Vigabatrin 500mg is a prescription medicine used with other treatments in adults and children 2 years of age and older with refractory complex partial seizures (CPS) who have not responded well enough to several other treatments and if the possible benefits outweigh the risk of vision loss. Vigabatrin  should not be the first medicine used to treat CPS.Because Vigabatrin  might cause permanent vision loss, it is available to healthcare providers and patients only under a special program called the Vigabatrin Risk Evaluation and Mitigation Strategy (REMS) Program. Your healthcare provider will explain the details of this Program to you.Vigabatrin  can damage the vision of anyone who takes it. Some people can have severe loss particularly to their ability to see to the side when looking straight ahead (peripheral vision). With severe vision loss, you may only be able to see things straight in front of you (sometimes called "tunnel vision"). You may also have blurry vision. If this happens, it will not get better.Tell your healthcare provider right away if you (or your child): might not be seeing as well as before starting Vigabatrin ; start to trip, bump into things, or are more clumsy than usual; are surprised by people or things coming in front of you that seem to come out of nowhere; or if your baby is acting differently than normal. These changes can mean that vision damage has occurred.It is recommended that your healthcare provider test your (or your child’s) vision before or within 4 weeks after starting Vigabatrin , and at least every 3 months during treatment until Vigabatrin  is stopped. It is also recommended that vision be tested about 3 to 6 months after Vigabatrin  is stopped. Your vision loss may get worse after you stop taking Vigabatrin . It is difficult to test vision in babies, but to the extent possible, all babies should have their vision tested. Your healthcare provider will determine if testing can be done. Regular vision testing is important because damage can happen before any changes are noticed.Vision tests cannot prevent the vision damage that can happen with Vigabatrin , but they do allow Vigabatrin  to be stopped if vision has gotten worse. Even these regular vision tests may not show vision damage before it is severe and permanent. Parents, caregivers, and healthcare providers may not recognize the symptoms, or find vision loss in babies, until it is severe.If vision tests are not done regularly, your healthcare provider may stop prescribing Vigabatrin  for you (or your child). Some people are not able to complete vision testing. If vision testing cannot be done, your healthcare provider may continue prescribing Vigabatrin , but will not be able to watch for any vision loss.Brain pictures taken by magnetic resonance imaging (MRI) show changes in some babies after they are given Vigabatrin . It is not known if these changes are harmful.A type of swelling in the brain called Intramyelinic Edema (IME) has been seen in autopsy examination of babies treated with vigabatrin.Like other antiepileptic drugs, Vigabatrin  may cause suicidal thoughts and actions in some people. Call a healthcare provider right away if you (or your child) have any symptoms, especially sudden changes in mood, behaviors, thoughts or feelings, and especially if they are new, worse, or worry you.Do not stop Vigabatrin  without first talking to a healthcare provider. Stopping Vigabatrin  suddenly can cause seizures that will not stop.Vigabatrin  can cause serious side effects such as low red blood cell counts (anemia), sleepiness and tiredness, nerve problems, weight gain, and swelling. Because Vigabatrin  causes sleepiness and tiredness, do not drive, operate machinery, or perform any hazardous task, unless it is decided that these things can be done safely.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested

Koselugo (Selumetinib 25mg,10mg)

Koselugo (Selumetinib  25mg,10mg)
  • Koselugo (Selumetinib  25mg,10mg)
  • Koselugo (Selumetinib  25mg,10mg)
Ask For Price
Product Price :Get Latest Price

Product Details:

Minimum Order Quantity1 Bottle
CompositionSelumetinib
FormCapsule
Packaging Size60 Capsule
Brand NameKOSELUGO
DosageTake KOSELUGO Capsule only as per the dose and duration suggested by your doctor
Packaging TypeBottle
Deals inThird Party Manufacturing
Type Of MedicinesAllopathic
TreatmentNeurofibroma

Koselugo (Selumetinib 25mg,10mg) is a prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery. It is not known if Koselugo is safe and effective in children under 2 years of age. IMPORTANT SAFETY INFORMATION Before taking Koselugo, tell your healthcare provider about all of your medical conditions, including if you: have heart problems have eye problems are pregnant or plan to become pregnant. Koselugo can harm your unborn baby Females who could become pregnant and males with female partners who could become pregnant should use effective birth control (contraception) during treatment with Koselugo and for 1 week after your last dose Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with Koselugo are breastfeeding or plan to breastfeed. It is not known if Koselugo passes into your breast milk Do not breastfeed during treatment with Koselugo and for 1 week after your last dose Talk to your healthcare provider about the best way to feed your baby during this time Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your healthcare provider if you are taking aspirin, blood thinners, or other medicines to treat blood clots. Koselugo contains vitamin E, which may increase your risk of bleeding. Koselugo may cause serious side effects, including: Heart problems. Koselugo can lower the amount of blood pumped by your heart, which is common and can also be severe. Your healthcare provider will do tests before and during treatment with Koselugo to check how well your heart is working. Tell your healthcare provider right away if you get any of the following signs or symptoms: persistent coughing or wheezing shortness of breath swelling of your ankles and feet tiredness increased heart rate Eye problems. Koselugo can cause eye problems that can lead to blindness. Your healthcare provider will check your vision before and during treatment with Koselugo. Tell your healthcare provider right away if you get any of the following signs or symptoms: blurred vision loss of vision dark spots in your vision (floaters) other changes to your vision Severe diarrhea. Diarrhea is common with Koselugo and can also be severe. Tell your healthcare provider right away the first time that you get diarrhea during treatment with Koselugo. Your healthcare provider may give you medicine to help control your diarrhea and may tell you to drink more fluids. Skin rash. Skin rashes are common with Koselugo and can also be severe. Tell your healthcare provider if you get any of the following signs or symptoms: rash that covers a large area of your body peeling skin blisters Muscle problems (rhabdomyolysis). Muscle problems are common with Koselugo and can also be severe. Treatment with Koselugo may increase the level of a muscle enzyme in your blood, which may be a sign of muscle damage. Your healthcare provider should do a blood test to check your muscle enzyme levels before you start taking Koselugo and during treatment. Tell your healthcare provider right away if you get any of the following signs or symptoms: muscle aches or pain muscle spasms and weakness dark, reddish urine Your healthcare provider may change your dose, temporarily stop, or permanently ask you to stop taking Koselugo if you have any of these side effects. The most common side effects of Koselugo are: vomiting stomach pain nausea dry skin feeling of tiredness, weakness, or lacking energy muscle and bone pain fever inflammation of the mouth headache redness around the fingernails itching These are not all the possible side effects of Koselugo.
Request
Callback


Additional Information:

  • Production Capacity: NA
  • Delivery Time: Immediate
  • Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO’s TRIPS agreement to which India is a Signatory. On this page we have made an “Honest Reference” of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.
Yes! I am Interested
X

Explore More Product

View All Product


Reach Us
Rakshit Jain (Sales & Marketing Manager)
Bull Pharmachem
No. 64C, Dhan Sadan Co Operative Housing Society, 2nd Floor
Kalbadevi, Mumbai - 400002, Maharashtra, India


Call Us


Send E-mail